Fidelity Investments’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.85M | Sell |
276,778
-66,959
| -19% | -$1.6M | ﹤0.01% | 2196 |
|
|
2025
Q4 | $8.02M | Sell |
343,737
-18,480
| -5% | -$412K | ﹤0.01% | 2112 |
|
|
2025
Q3 | $7.14M | Sell |
362,217
-146,896
| -29% | -$3.02M | ﹤0.01% | 2120 |
|
|
2025
Q2 | $11M | Buy |
509,113
+189,234
| +59% | +$4.47M | ﹤0.01% | 1895 |
|
|
2025
Q1 | $7.76M | Buy |
319,879
+207,397
| +184% | +$4.67M | ﹤0.01% | 2007 |
|
|
2024
Q4 | $2.35M | Buy |
112,482
+13,902
| +14% | +$299K | ﹤0.01% | 2391 |
|
|
2024
Q3 | $1.96M | Buy |
98,580
+19,270
| +24% | +$357K | ﹤0.01% | 2407 |
|
|
2024
Q2 | $1.23M | Buy |
79,310
+5,480
| +7% | +$85.3K | ﹤0.01% | 2465 |
|
|
2024
Q1 | $1.18M | Buy |
73,830
+60,906
| +471% | +$918K | ﹤0.01% | 2463 |
|
|
2023
Q4 | $217K | Sell |
12,924
-18,107
| -58% | -$248K | ﹤0.01% | 2942 |
|
|
2023
Q3 | $363K | Sell |
31,031
-41,833
| -57% | -$560K | ﹤0.01% | 2715 |
|
|
2023
Q2 | $979K | Buy |
72,864
+57,019
| +360% | +$821K | ﹤0.01% | 2480 |
|
|
2023
Q1 | $263K | Buy |
15,845
+301
| +2% | +$4.97K | ﹤0.01% | 2890 |
|
|
2022
Q4 | $289K | Sell |
15,544
-26,905
| -63% | -$414K | ﹤0.01% | 2896 |
|
|
2022
Q3 | $544K | Buy |
42,449
+38,231
| +906% | +$453K | ﹤0.01% | 2760 |
|
|
2022
Q2 | $30K | Buy |
4,218
+822
| +24% | +$6.03K | ﹤0.01% | 3744 |
|
|
2022
Q1 | $28K | Buy |
3,396
+1,377
| +68% | +$9.73K | ﹤0.01% | 3892 |
|
|
2021
Q4 | $14K | Sell |
2,019
-400
| -17% | -$2.63K | ﹤0.01% | 3545 |
|
|
2021
Q3 | $12K | Buy |
2,419
+1,266
| +110% | +$6.92K | ﹤0.01% | 3561 |
|
|
2021
Q2 | $7K | Sell |
1,153
-647
| -36% | -$3.34K | ﹤0.01% | 3625 |
|
|
2021
Q1 | $8K | Hold |
1,800
| – | – | ﹤0.01% | 3429 |
|
|
2020
Q4 | $6K | Hold |
1,800
| – | – | ﹤0.01% | 3399 |
|
|
2020
Q3 | $5K | Buy |
1,800
+1,082
| +151% | +$4.23K | ﹤0.01% | 3308 |
|
|
2020
Q2 | $4K | Buy |
718
+575
| +402% | +$2.58K | ﹤0.01% | 3264 |
|
|
2020
Q1 | $1K | Sell |
143
-60
| -30% | -$246 | ﹤0.01% | 3470 |
|
|
2019
Q4 | $1K | Hold |
203
| – | – | ﹤0.01% | 3631 |
|
|
2019
Q3 | $1K | Sell |
203
-343
| -63% | -$1.83K | ﹤0.01% | 3628 |
|
|
2019
Q2 | $2K | Buy |
+546
| New | +$2.36K | ﹤0.01% | 3507 |
|
|
2018
Q1 | – | Sell |
-300,000
| Closed | -$1.17M | – | 2674 |
|
|
2017
Q4 | $1.17M | Hold |
300,000
| – | – | ﹤0.01% | 2428 |
|
|
2017
Q3 | $756K | Hold |
300,000
| – | – | ﹤0.01% | 2440 |
|
|
2017
Q2 | $828K | Buy |
+300,000
| New | +$626K | ﹤0.01% | 2452 |
|
Other funds holding CPRX
VCM
DM
VPM
Fidelity Investments's CPRX Position: Q1 2026 in Review
Fidelity Investments reduced its Catalyst Pharmaceutical (CPRX) stake by 19% in Q1 2026, selling an estimated $1.6M and leaving 276,778 shares worth $6.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2196.
Fidelity Investments first reported a position in CPRX in Q2 2017 and has held it in 31 quarters since. The position peaked at $11M in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Fidelity Investments held 276,778 shares of Catalyst Pharmaceutical worth $6.85M as of Q1 2026.
- Fidelity Investments sold 66,959 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.6M.
- Catalyst Pharmaceutical made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2196 holding.
- Fidelity Investments first reported a position in Catalyst Pharmaceutical in Q2 2017 and has held it in 31 quarters since.
- Fidelity Investments's Catalyst Pharmaceutical position peaked at $11M in Q2 2025.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.